Erratum: Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis

Jesus Aibar; Sam Schulman

doi:10.1055/s-0042-1757330

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2021; 47(06): e1-e2
DOI: 10.1055/s-0042-1757330

Erratum

Erratum: Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis

Jesus Aibar

¹Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

²Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada

,

Sam Schulman

²Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada

³Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

› Author Affiliations

Abstract

Full Text

PDF Download

It has been brought to the publisher's attention that [Fig. 4] published in the above article in Seminars In Thrombosis And Hemostasis, Volume 47, Number 6 (DOI: 10.1055/S-0041-1725057) is incorrect. The corrected figure appears as follows and is placed below.

Fig. 4 Forest plots of arterial thrombosis. Comparisons between single antiplatelet therapy (SAPT) versus vitamin K antagonist (VKA) (A), dual antiplatelet therapy (DAPT) versus SAPT (B), VKA plus SAPT versus SAPT (C), VKA plus SAPT versus VKA (D), VKA international normalized ratio (INR) 2–3 versus VKA INR 3–4 (E), DAPT versus VKA plus SAPT (F), VKA versus non-VKA oral anticoagulant (NOAC) (G).

Figures

Fig. 4 Forest plots of arterial thrombosis. Comparisons between single antiplatelet therapy (SAPT) versus vitamin K antagonist (VKA) (A), dual antiplatelet therapy (DAPT) versus SAPT (B), VKA plus SAPT versus SAPT (C), VKA plus SAPT versus VKA (D), VKA international normalized ratio (INR) 2–3 versus VKA INR 3–4 (E), DAPT versus VKA plus SAPT (F), VKA versus non-VKA oral anticoagulant (NOAC) (G).